SoftOx Solutions AS — Board/Management Information 2022

Dec 20, 2022

SoftOx Solutions AS: Announces organizational changes

SoftOx Solutions AS: Announces organizational changes

Oslo – December 20, 2022: The Board of Directors of SoftOx Solutions AS ("SoftOx" or the "Company"), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, announces that Christian Harstad has been appointed as the Interim Chief Executive Officer.

Christian Harstad has a long military career including serving as a submarine commanding officer and roles in the Norwegian special forces, US Joint Forces Command, US Naval War College, Norwegian Defence Staff, and the Norwegian Ministry of Defence. He retired from the Military as Flag Officer and second-in-command for Norwegian Special Operations Forces. In September 2022, Harstad joined SoftOx as the Project Director for SoftOx Defense Solutions AS.

Geir Almås, Executive Chairman of the Board, said “As recently published, I will step down from my current role as CEO and transition to Executive chairman of SoftOx and to focus my efforts on funding and strategic development of the company. Based on Harstad’s background, prior experience, skill set and extensive network, I feel confident that he is a very good candidate for the job. We are thrilled to have recruited him to lead the company as it embarks on its next strategic steps for collaboration with major defence institutions including the European Defence Fund (EDF) and the US Naval Medical Research Center.”

Christian Harstad added: “I am very pleased that Geir and the Board have given me this opportunity. SoftOx is in a unique position both on the wound care and the infectious disease segments. Working together with Geir, I believe we have a strategy that will move the company forward in a very interesting market. In the infectious disease segment, we have established ourselves as one of the main technologies in a consortium with the backing of EU whereas we are working together with the US Naval Medical Research Center on the development of treatment for chronic wounds. With partners like these, we have positioned the Company well and laid the groundwork for bringing very important capabilities to the military and civilian market.”

Christian Harstad will commence as interim CEO on January 1, 2023.

In addition, the Company’s Chief Financial Officer Kristine Rød is leaving the company in order to pursue other opportunities. As of January 1, 2023, Harald Sætvedt will be the company’s CFO.

“I am very happy to welcome Harald Sætvedt as our new CFO. Sætvedt has worked with SoftOx on strategic questions for two years and knows the company well. With Sætvedt’s solid experience from international corporate finance, Harstad’s international leadership experience in addition to support from the new Board of Directors, we feel confident the company shall manage its planned international journey. At the same time, I also want to thank Kristine Rød for her contributions and commitment to SoftOx and wish her all the best for the future,” said Geir Almås, Executive Chairman of SoftOx.

For any questions or interview requests, please contact:

Geir Almås, CEO of SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance.

For more information on SoftOx, visit www.soft-ox.com